Molecular Cardioprotection: How Pediatric Myosin Inhibition Redefines the Economics of Congenital Heart Care
Dr. Dereck Mush, MD, MBA
ArteraAI
Develops AI prognostic tests to personalize cancer treatment plans and improve outcomes.
What they do
ArteraAI develops digital prognostic and predictive tests utilizing artificial intelligence to analyze pathology images. Healthcare providers use these tests to personalize prostate cancer treatment, determining which patients will benefit from hormone therapy or if they can safely avoid intensive treatments.
The record
- Vertical
- Oncology
- Sub-segment
- Precision medicine platform
- Product type
- Software as a medical device
- Stage
- Series B
- Headquarters
- San Francisco, United States
- Region
- North America
- Founded
- 2020
- Total funding
- $110M raised
Notable investors: Coatue, Breyer Capital, Section 32, Marc Benioff.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
From Algae to Neural Circuits: What the 2026 Medicine Nobel Means for Optogenetics
Dr. Dereck Mush, MD, MBA
Overcoming the Solvent Front: How Jideytro Validates Nuvalent's Precision Oncology Playbook
Dr. Dereck Mush, MD, MBA
Beyond PD-L1: How the I3LUNG Consortium Validated Multimodal AI in 2,365 Advanced Lung Cancer Patients
Dr. Dereck Mush, MD, MBA